Assefa Mulu Baye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Assefa Mulu Baye has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Edessa Diriba
Pharmaceutical and Medical Equipment Directorate, Ministry of Health, Addis Ababa, Ethiopia
4 shared publicationsMahdi Abdella
Pharmaceutical and Medical Equipment Directorate, Ministry of Health, Addis Ababa, Ethiopia
4 shared publications- Muluken Nigatu Selam
Department of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
4 shared publications Regasa Bayisa
Pharmaceutical and Medical Equipment Directorate, Ministry of Health, Addis Ababa, Ethiopia
4 shared publications- Andualem Ababu
Pharmaceutical and Medical Equipment Directorate (PMED), Ministry of Health, Addis Ababa, Ethiopia
3 shared publications Adem Y. Dawed
Division of Population Health and Genomics Ninewells Hospital and School of Medicine, University of Dundee Dundee UK
2 shared publications
Latest Publications
- Open Access
- 2 April 2025
- Published by Wiley in Journal of Diabetes
- Vol. 17 (4) , e70078
Comparative Analysis of Type 2 Diabetes Prevalence and Clinical Profiles in Ethiopia and Nigeria
Aims: We aimed to determine the prevalence of diabetes and the clinical profiles of Type 2 diabetes in Ethiopia and Nigeria.Methods: A community‐based cross‐sectional study was carried out from November 01, 2020 to October 21, 2021 among 1727 participants using a multistage sampling method. The WHO's STEPs tool was employed. Both fasting and oral glucose tolerance tests were used for screening and American Diabetes Association's (ADA's) diagnostic criteria was used. Stata version 17 was used for analysis. Analysis of Variance (ANOVA) and the Chi‐square test were used to compare variables. Significance was declared at a p‐value less than 0.05.Result: Of the surveyed participants, 872 (50.5%) were men and the mean age was 44.6 years. The overall prevalence of prediabetes and diabetes was 15.8% and 7.0%, respectively. Impaired fasting glycaemia and glucose tolerance were 11.8% and 11.5%, respectively. The prevalence of newly diagnosed diabetes was 3.4% by fasting and 4.0% by oral glucose tolerance test. Participants with normal blood glucose were younger and had a lower weight, body mass index (BMI), waist circumference, diastolic, and systolic blood pressure, and history of hypertension than those with prediabetes and diabetes.Conclusion: In the present study, there is a notably high diabetes and prediabetes prevalence in the study settings. Individuals with diabetes in Ethiopia compared to Nigeria and the West have different anthropometric and clinical profiles characterized by a young age of onset, leanness, lower BMI, and waist circumference. Hence, the management of diabetes shall be tailored to the unique physiologic and clinical profiles of the population.
- 2 April 2025
- Published by Wiley in Journal of Diabetes
- Vol. 17 (4) , e70078
Open AccessComparative Analysis of Type 2 Diabetes Prevalence and Clinical Profiles in Ethiopia and Nigeria
Aims: We aimed to determine the prevalence of diabetes and the clinical profiles of Type 2 diabetes in Ethiopia and Nigeria.Methods: A community‐based cross‐sectional study was carried out from November 01, 2020 to October 21, 2021 among 1727 participants using a multistage sampling method. The WHO's STEPs tool was employed. Both fasting and oral glucose tolerance tests were used for screening and American Diabetes Association's (ADA's) diagnostic criteria was used. Stata version 17 was used for analysis. Analysis of Variance (ANOVA) and the Chi‐square test were used to compare variables. Significance was declared at a p‐value less than 0.05.Result: Of the surveyed participants, 872 (50.5%) were men and the mean age was 44.6 years. The overall prevalence of prediabetes and diabetes was 15.8% and 7.0%, respectively. Impaired fasting glycaemia and glucose tolerance were 11.8% and 11.5%, respectively. The prevalence of newly diagnosed diabetes was 3.4% by fasting and 4.0% by oral glucose tolerance test. Participants with normal blood glucose were younger and had a lower weight, body mass index (BMI), waist circumference, diastolic, and systolic blood pressure, and history of hypertension than those with prediabetes and diabetes.Conclusion: In the present study, there is a notably high diabetes and prediabetes prevalence in the study settings. Individuals with diabetes in Ethiopia compared to Nigeria and the West have different anthropometric and clinical profiles characterized by a young age of onset, leanness, lower BMI, and waist circumference. Hence, the management of diabetes shall be tailored to the unique physiologic and clinical profiles of the population.
- Open Access
- 25 March 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1501383
Performance of fasting plasma glucose for community-based screening of undiagnosed diabetes and pre-diabetes in sub-Saharan Africa
Introduction: Early diabetes screening is critical in sub-Saharan Africa (SSA), where the prevalence is increasing, yet a large proportion of cases remain undiagnosed. This study aimed to evaluate the performance of fasting plasma glucose (FPG) in screening diabetes and/or prediabetes compared to the 2-hour plasma glucose (2-h PG)-level in SSA.Methods: Data from a population-based, cross-sectional diabetes screening survey involving 1550 individuals in Butajira, Ethiopia, and Enugu state, Nigeria were analyzed. Fasting plasma glucose and a 2-hour 75-g oral glucose tolerance test (OGTT) were utilized for diabetes screening. In addition, we determined and plotted the receiver operating characteristic curve for FPG against the reference standard 2-h PG to evaluate the screening tool’s sensitivity and specificity.Results: The mean (SD) age of the study participants was 44.5 (± 16.43) years, with men comprising 50.4% of the cohort. Among 1550 individuals analyzed, 4.6% and 16.8% demonstrated diabetes and prediabetes, respectively, as identified by either FPG or 2-h PG. The agreement between FPG and 2-h PG in identifying diabetes and prediabetes was moderate, with kappa statistic of 0.56 (95% CI, 0.51 – 0.61; p<0.0001) for diabetes and 0.45 (95% CI, 0.40 – 0.50; p<0.0001) for prediabetes. FPG failed to detect 34.1% of all prediabetes and 44.4% of all diabetes cases. The sensitivity of FPG in identifying diabetes cases was 44.3% at a cut-off 126 mg/dL with a specificity of 99.3%. We identified the optimal FPG cut-off for detecting newly identified diabetes cases using 2-h PG to be 105 mg/dL associated with a sensitivity and specificity of 67.2% and 94.0%, respectively.Conclusion: FPG was able to correctly identify 99.3% of individuals with no diabetes but a significant percentage of diabetes cases would have remained undiagnosed if only FPG had been utilized instead of the 2-h PG. The use of 2-h PG test is recommended to diagnose diabetes in older individuals, females and non-obese persons who would be missed if tested by only FPG. Lowering the cut-off value for FPG to 105 mg/dL substantially increases the identification of individuals with diabetes, thus improving the effectiveness of FPG as a screening test for type 2 diabetes.
- 25 March 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1501383
Open AccessPerformance of fasting plasma glucose for community-based screening of undiagnosed diabetes and pre-diabetes in sub-Saharan Africa
Introduction: Early diabetes screening is critical in sub-Saharan Africa (SSA), where the prevalence is increasing, yet a large proportion of cases remain undiagnosed. This study aimed to evaluate the performance of fasting plasma glucose (FPG) in screening diabetes and/or prediabetes compared to the 2-hour plasma glucose (2-h PG)-level in SSA.Methods: Data from a population-based, cross-sectional diabetes screening survey involving 1550 individuals in Butajira, Ethiopia, and Enugu state, Nigeria were analyzed. Fasting plasma glucose and a 2-hour 75-g oral glucose tolerance test (OGTT) were utilized for diabetes screening. In addition, we determined and plotted the receiver operating characteristic curve for FPG against the reference standard 2-h PG to evaluate the screening tool’s sensitivity and specificity.Results: The mean (SD) age of the study participants was 44.5 (± 16.43) years, with men comprising 50.4% of the cohort. Among 1550 individuals analyzed, 4.6% and 16.8% demonstrated diabetes and prediabetes, respectively, as identified by either FPG or 2-h PG. The agreement between FPG and 2-h PG in identifying diabetes and prediabetes was moderate, with kappa statistic of 0.56 (95% CI, 0.51 – 0.61; p<0.0001) for diabetes and 0.45 (95% CI, 0.40 – 0.50; p<0.0001) for prediabetes. FPG failed to detect 34.1% of all prediabetes and 44.4% of all diabetes cases. The sensitivity of FPG in identifying diabetes cases was 44.3% at a cut-off 126 mg/dL with a specificity of 99.3%. We identified the optimal FPG cut-off for detecting newly identified diabetes cases using 2-h PG to be 105 mg/dL associated with a sensitivity and specificity of 67.2% and 94.0%, respectively.Conclusion: FPG was able to correctly identify 99.3% of individuals with no diabetes but a significant percentage of diabetes cases would have remained undiagnosed if only FPG had been utilized instead of the 2-h PG. The use of 2-h PG test is recommended to diagnose diabetes in older individuals, females and non-obese persons who would be missed if tested by only FPG. Lowering the cut-off value for FPG to 105 mg/dL substantially increases the identification of individuals with diabetes, thus improving the effectiveness of FPG as a screening test for type 2 diabetes.
- Open Access
- 31 July 2024
- Published by Springer Nature in Thrombosis Journal
- Vol. 22 (1) , 1
Correction: Outcomes of deep venous thrombosis management and associated factors among patients in tertiary hospitals in Addis Ababa, Ethiopia: a multicenter retrospective cohort study
- 31 July 2024
- Published by Springer Nature in Thrombosis Journal
- Vol. 22 (1) , 1
Open AccessCorrection: Outcomes of deep venous thrombosis management and associated factors among patients in tertiary hospitals in Addis Ababa, Ethiopia: a multicenter retrospective cohort study
- Open Access
- 12 July 2024
- Published by Springer Nature in Thrombosis Journal
- Vol. 22 (1) , 1-10
Outcomes of deep venous thrombosis management and associated factors among patients in tertiary hospitals in Addis Ababa, Ethiopia: a multicenter retrospective cohort study
Background: Pulmonary embolism (PE) and deep venous thrombosis (DVT) are the two most important manifestations of venous thromboembolism (VTE). DVT remains a significant condition since associated morbidity is significant and has elevated healthcare-related costs. Methods: A retrospective cohort study was conducted among DVT patients admitted to Tikur Anbessa Specialized Hospital, Zewditu Memorial Hospital and St. Paul’s Hospital Millennium Medical College on follow-up from July 1, 2017, to July 01, 2020. Data on sociodemographic characteristics, types of DVT, laboratory findings, medications, risk factors of DVT, complications and outcomes of DVT were collected. The data were analyzed using SPSS version 25. Multivariate logistic regression analysis was conducted to determine predictors of DVT recurrence and major bleeding. A P value < 0.05 was considered to identify significant predictors. Results: The mean age of the participants was 45.2 years, with SD of 15.36. The major causes of DVT included immobilization (29.9%), previous surgery (27.5%) and cancer (21.1%). The DVT recurrence rate was 22.5%. Nine (2.2%) of the participants died, and 19.9% developed complications. Bilateral DVT (Adjusted odds ratio (AOR) = 2.8, 95% Confidence interval (CI) = 1.14, 6.66), obesity (AOR = 3.3, 95% CI = 1.15, 9.59), hypertension (AOR = 6.5, 95% CI = 2.90, 14.70) and retroviral infection (AOR = 6.3, 95% CI = 2.34, 16.94) were predictors of recurrent DVT. Nineteen (4.7%) patients had major bleeding, and patients with bilateral DVT, active cancer and terminal age had an increased risk of major bleeding. Conclusions: The overall DVT recurrence rate was alarmingly high and further complicated by PE, post thrombotic syndrome and chronic vein insufficiency, resulting in a 2.2% death rate. Major bleeding after DVT and PE remained high. Close monitoring should be performed for patients with advanced age, active cancer, bilateral DVT, retroviral infection, obesity and hypertension to prevent the recurrence of DVT and major bleeding.
- 12 July 2024
- Published by Springer Nature in Thrombosis Journal
- Vol. 22 (1) , 1-10
Open AccessOutcomes of deep venous thrombosis management and associated factors among patients in tertiary hospitals in Addis Ababa, Ethiopia: a multicenter retrospective cohort study
Background: Pulmonary embolism (PE) and deep venous thrombosis (DVT) are the two most important manifestations of venous thromboembolism (VTE). DVT remains a significant condition since associated morbidity is significant and has elevated healthcare-related costs. Methods: A retrospective cohort study was conducted among DVT patients admitted to Tikur Anbessa Specialized Hospital, Zewditu Memorial Hospital and St. Paul’s Hospital Millennium Medical College on follow-up from July 1, 2017, to July 01, 2020. Data on sociodemographic characteristics, types of DVT, laboratory findings, medications, risk factors of DVT, complications and outcomes of DVT were collected. The data were analyzed using SPSS version 25. Multivariate logistic regression analysis was conducted to determine predictors of DVT recurrence and major bleeding. A P value < 0.05 was considered to identify significant predictors. Results: The mean age of the participants was 45.2 years, with SD of 15.36. The major causes of DVT included immobilization (29.9%), previous surgery (27.5%) and cancer (21.1%). The DVT recurrence rate was 22.5%. Nine (2.2%) of the participants died, and 19.9% developed complications. Bilateral DVT (Adjusted odds ratio (AOR) = 2.8, 95% Confidence interval (CI) = 1.14, 6.66), obesity (AOR = 3.3, 95% CI = 1.15, 9.59), hypertension (AOR = 6.5, 95% CI = 2.90, 14.70) and retroviral infection (AOR = 6.3, 95% CI = 2.34, 16.94) were predictors of recurrent DVT. Nineteen (4.7%) patients had major bleeding, and patients with bilateral DVT, active cancer and terminal age had an increased risk of major bleeding. Conclusions: The overall DVT recurrence rate was alarmingly high and further complicated by PE, post thrombotic syndrome and chronic vein insufficiency, resulting in a 2.2% death rate. Major bleeding after DVT and PE remained high. Close monitoring should be performed for patients with advanced age, active cancer, bilateral DVT, retroviral infection, obesity and hypertension to prevent the recurrence of DVT and major bleeding.
- Open Access
- 1 March 2024
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 17, 1157-1169
Evaluation of Statin Indication and Dose Intensification Among Type 2 Diabetic Patients at a Tertiary Hospital
Background: Diabetes mellitus (DM) increases cardiovascular disease (CVD) incidence and mortality. While guidelines endorse statin use in type 2 DM (T2DM) to mitigate cardiovascular risks and mortality, challenges like statin initiation and prompt treatment adjustments affect patient outcomes. This study aimed to assess the appropriateness of indications for and dose intensification of statin therapy among T2DM patients at Tikur Anbessa Specialized Hospital (TASH). Methodology: A hospital-based cross-sectional study was conducted from April 1 to June 30 2020. In total, 405 T2DM patients were selected using a systematic random sampling technique. The data were analyzed using SPSS version 26.0. An adjusted odds ratio (OR) was used and a 95% confidence interval (CI) and p-values of < 0.05 were utilized to determine statistical significance. Results: Of the total 405 participants, 346 (85.4%) started taking statins for primary or secondary prevention purposes. Indication for statin use was appropriate in 96.2% patients, while for 216 (62.4%) patients their doses were appropriately intensified. Predictors of the inappropriateness of statin use were an atherosclerotic cardiovascular disease (ASCVD) score of ≥ 7.5% (AOR=0.28; 95% CI: 0.102– 0.738, p=0.01), the presence of dyslipidemia (AOR=4.48; 95% CI: 1.85– 10.84; p=0.001), initiation of aspirin therapy (AOR=3.7; 95% CI: 1.522– 9.144; p=0.004), and an LDL-cholesterol level of 70– 189 mg/dL (AOR=0.124; 95% CI: 0.042– 0.365; p=0.001). DM duration of ≥ 10 years (AOR=2.51; 95% CI: 1.35– 4.66, p=0.004), male gender (AOR=2.04; 95% CI: 1.16– 3.58, p=0.013), age ≥ 65 years (AOR=2.15; 95% CI: 1.23– 3.75, p=0.007) and uncontrolled blood pressure (AOR=2.09; 95% CI: 1.07– 4.08, p=0.031) were associated with inappropriate statin intensification. Conclusion: The study found that indication of statins was optimal and about two-thirds of patients had their doses appropriately intensified. Monitoring is needed to avoid inappropriate intensification of statin therapy, particularly in patients with longer diabetes duration, those of male gender and advanced age, and those with uncontrolled blood pressure.
- 1 March 2024
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 17, 1157-1169
Open AccessEvaluation of Statin Indication and Dose Intensification Among Type 2 Diabetic Patients at a Tertiary Hospital
Background: Diabetes mellitus (DM) increases cardiovascular disease (CVD) incidence and mortality. While guidelines endorse statin use in type 2 DM (T2DM) to mitigate cardiovascular risks and mortality, challenges like statin initiation and prompt treatment adjustments affect patient outcomes. This study aimed to assess the appropriateness of indications for and dose intensification of statin therapy among T2DM patients at Tikur Anbessa Specialized Hospital (TASH). Methodology: A hospital-based cross-sectional study was conducted from April 1 to June 30 2020. In total, 405 T2DM patients were selected using a systematic random sampling technique. The data were analyzed using SPSS version 26.0. An adjusted odds ratio (OR) was used and a 95% confidence interval (CI) and p-values of < 0.05 were utilized to determine statistical significance. Results: Of the total 405 participants, 346 (85.4%) started taking statins for primary or secondary prevention purposes. Indication for statin use was appropriate in 96.2% patients, while for 216 (62.4%) patients their doses were appropriately intensified. Predictors of the inappropriateness of statin use were an atherosclerotic cardiovascular disease (ASCVD) score of ≥ 7.5% (AOR=0.28; 95% CI: 0.102– 0.738, p=0.01), the presence of dyslipidemia (AOR=4.48; 95% CI: 1.85– 10.84; p=0.001), initiation of aspirin therapy (AOR=3.7; 95% CI: 1.522– 9.144; p=0.004), and an LDL-cholesterol level of 70– 189 mg/dL (AOR=0.124; 95% CI: 0.042– 0.365; p=0.001). DM duration of ≥ 10 years (AOR=2.51; 95% CI: 1.35– 4.66, p=0.004), male gender (AOR=2.04; 95% CI: 1.16– 3.58, p=0.013), age ≥ 65 years (AOR=2.15; 95% CI: 1.23– 3.75, p=0.007) and uncontrolled blood pressure (AOR=2.09; 95% CI: 1.07– 4.08, p=0.031) were associated with inappropriate statin intensification. Conclusion: The study found that indication of statins was optimal and about two-thirds of patients had their doses appropriately intensified. Monitoring is needed to avoid inappropriate intensification of statin therapy, particularly in patients with longer diabetes duration, those of male gender and advanced age, and those with uncontrolled blood pressure.
- Open Access
- 17 October 2023
- Published by Springer Nature in Research Square
Evaluation of statin indication and dose intensification among type 2 diabetic patients at Tikur Anbessa Specialized Hospital
Background Diabetes Mellitus (DM) increases the incidence and mortality of cardiovascular diseases (CVD) by a 2 to 4-fold compared to people without DM. Although clinical practice guidelines recommend the use of statin in type 2 DM (T2DM) patients to reduce cardiovascular risks and all-cause mortality, statin intolerance and other factors may lead to treatment discontinuation, switching among statin agents, dose adjustments, or the need for augmentation of the statin regimen impacting therapeutic benefits and patient outcomes. This study aimed to assess the appropriateness of indication and dose intensification of statin therapy among T2DM patients at Tikur Anbessa Specialized Hospital (TASH). Methodology : A hospital-based cross-sectional study design was conducted among 405 T2DM patients from 01 April to 30 June 2020. A systematic random sampling technique was implemented to recruit study participants who had been on follow-up during the study period in TASH. Adjusted odds ratio (OR) was used to measure the association of dependent and independent variables at 95% confidence interval (CI) and P-values of < 0.05 were utilized to determine the statistical significance. Results Statins were initiated for 85.4% of patients. Majority (82.9%) of patients were indicated statin for primary prevention and the estimated 10-year ASCVD scores were ≥ 7.5% among 60.1% of patients. Among 346 patients on statin therapy, the indication was appropriate in 333 (96.2%) patients while 216 (62.4%) patients were appropriately intensified. Predictors for appropriateness of statin indication were ASCVD score ≥ 7.5% (AOR = 0.275; 95% CI: 0.102–0.738, p = 0.01), presence of dyslipidemia (AOR = 4.48; 95%CI: 1.85–10.84; p = 0.001), initiation of aspirin therapy (AOR = 3.7; 95%CI: 1.522–9.144; p = 0.004), and LDL-cholesterol level 70–189 mg/dL (AOR = 0.124; 95% CI:0.042–0.365; p = 0.001). Moreover, duration of illness (AOR = 3.22, 95% CI: 1.680-6.1351, P < 0.001) and history of vascular complications (AOR = 3.24, 95% CI: 1.085,9.708, P = 0.035) were associated with inappropriate dose intensification of statins. Conclusion The study found that indication of statins was generally in line with guidelines, but inappropriate statin dose intensification was linked to patients with longer duration of diabetes and vascular complications. Clinicians should consider dose titration of statins based on patient cardiovascular risk profile and routine laboratory results.
- 17 October 2023
- Published by Springer Nature in Research Square
Open AccessEvaluation of statin indication and dose intensification among type 2 diabetic patients at Tikur Anbessa Specialized Hospital
Background Diabetes Mellitus (DM) increases the incidence and mortality of cardiovascular diseases (CVD) by a 2 to 4-fold compared to people without DM. Although clinical practice guidelines recommend the use of statin in type 2 DM (T2DM) patients to reduce cardiovascular risks and all-cause mortality, statin intolerance and other factors may lead to treatment discontinuation, switching among statin agents, dose adjustments, or the need for augmentation of the statin regimen impacting therapeutic benefits and patient outcomes. This study aimed to assess the appropriateness of indication and dose intensification of statin therapy among T2DM patients at Tikur Anbessa Specialized Hospital (TASH). Methodology : A hospital-based cross-sectional study design was conducted among 405 T2DM patients from 01 April to 30 June 2020. A systematic random sampling technique was implemented to recruit study participants who had been on follow-up during the study period in TASH. Adjusted odds ratio (OR) was used to measure the association of dependent and independent variables at 95% confidence interval (CI) and P-values of < 0.05 were utilized to determine the statistical significance. Results Statins were initiated for 85.4% of patients. Majority (82.9%) of patients were indicated statin for primary prevention and the estimated 10-year ASCVD scores were ≥ 7.5% among 60.1% of patients. Among 346 patients on statin therapy, the indication was appropriate in 333 (96.2%) patients while 216 (62.4%) patients were appropriately intensified. Predictors for appropriateness of statin indication were ASCVD score ≥ 7.5% (AOR = 0.275; 95% CI: 0.102–0.738, p = 0.01), presence of dyslipidemia (AOR = 4.48; 95%CI: 1.85–10.84; p = 0.001), initiation of aspirin therapy (AOR = 3.7; 95%CI: 1.522–9.144; p = 0.004), and LDL-cholesterol level 70–189 mg/dL (AOR = 0.124; 95% CI:0.042–0.365; p = 0.001). Moreover, duration of illness (AOR = 3.22, 95% CI: 1.680-6.1351, P < 0.001) and history of vascular complications (AOR = 3.24, 95% CI: 1.085,9.708, P = 0.035) were associated with inappropriate dose intensification of statins. Conclusion The study found that indication of statins was generally in line with guidelines, but inappropriate statin dose intensification was linked to patients with longer duration of diabetes and vascular complications. Clinicians should consider dose titration of statins based on patient cardiovascular risk profile and routine laboratory results.
- Open Access
- 1 January 2022
- Published by Taylor & Francis in Integrated Pharmacy Research and Practice
- Vol. ume 11, 1-8
Prescribing Pattern of Dermatological Compounding in Ethiopia: The Case of ALERT Hospital
Background: Skin diseases are among the major contributors of disease burden in Ethiopia affecting individuals of all age. Extemporaneous compounding of topical medications serves as a necessary option to treat skin diseases when manufactured medications could not meet specific patient needs. Different classes of drugs are commonly used for the treatment of dermatologic diseases. Failure to periodically assess the prescribing pattern and patient needs may lead to inappropriate planning and implementation that ultimately compromise the service. Periodic prescription analysis for compounded medications helps to monitor the prescription pattern with respect to medication selection, disease condition, dosage form types and other relevant parameters. The current study was conducted to analyze the pattern of compounding prescriptions for dermatologicals in ALERT hospital. Methods: A cross-sectional design was conducted by retrospectively evaluating compounding prescription records of January and July, 2021. A total of 460 prescriptions in the hospital community pharmacy were systematically selected. Data related to disease pattern, product selection and dosage form type were extracted and analyzed. Data analysis was done using software for the statistical package for social science version 25.0. Results: A total of 441 prescriptions containing dermatological products for compounding were analyzed. Most patients were female (62.8%) and aged 30– 64 years (44.0%). Psoriasis (36.2%), acne vulgaris (15.3%), and rosacea (13.4%) were the top 3 skin diseases for which the compounding preparations were prescribed. Salicylic acid (38.0%) was the most frequently prescribed drug followed by betamethasone (20.2%); while white petrolatum (47.2%) was the most common diluting agent used for compounding. Conclusion: Psoriasis was the major dermatologic disease for compounding prescriptions and salicylic acid was the most frequent product used in compounding for treatment of the prescribed skin diseases.
- 1 January 2022
- Published by Taylor & Francis in Integrated Pharmacy Research and Practice
- Vol. ume 11, 1-8
Open AccessPrescribing Pattern of Dermatological Compounding in Ethiopia: The Case of ALERT Hospital
Background: Skin diseases are among the major contributors of disease burden in Ethiopia affecting individuals of all age. Extemporaneous compounding of topical medications serves as a necessary option to treat skin diseases when manufactured medications could not meet specific patient needs. Different classes of drugs are commonly used for the treatment of dermatologic diseases. Failure to periodically assess the prescribing pattern and patient needs may lead to inappropriate planning and implementation that ultimately compromise the service. Periodic prescription analysis for compounded medications helps to monitor the prescription pattern with respect to medication selection, disease condition, dosage form types and other relevant parameters. The current study was conducted to analyze the pattern of compounding prescriptions for dermatologicals in ALERT hospital. Methods: A cross-sectional design was conducted by retrospectively evaluating compounding prescription records of January and July, 2021. A total of 460 prescriptions in the hospital community pharmacy were systematically selected. Data related to disease pattern, product selection and dosage form type were extracted and analyzed. Data analysis was done using software for the statistical package for social science version 25.0. Results: A total of 441 prescriptions containing dermatological products for compounding were analyzed. Most patients were female (62.8%) and aged 30– 64 years (44.0%). Psoriasis (36.2%), acne vulgaris (15.3%), and rosacea (13.4%) were the top 3 skin diseases for which the compounding preparations were prescribed. Salicylic acid (38.0%) was the most frequently prescribed drug followed by betamethasone (20.2%); while white petrolatum (47.2%) was the most common diluting agent used for compounding. Conclusion: Psoriasis was the major dermatologic disease for compounding prescriptions and salicylic acid was the most frequent product used in compounding for treatment of the prescribed skin diseases.
- 1 July 2021
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 15 (4) , 102187
Magnitude of metabolic syndrome and its predictors among patients on second-generation antipsychotic drugs at six psychiatry clinics and mental hospitals, in Addis Ababa, Ethiopia, 2019; Multicenter cross-sectional study
- 1 July 2021
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 15 (4) , 102187
Magnitude of metabolic syndrome and its predictors among patients on second-generation antipsychotic drugs at six psychiatry clinics and mental hospitals, in Addis Ababa, Ethiopia, 2019; Multicenter cross-sectional study
- Open Access
- 28 April 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (4) , e0250020
Perspectives of compounding pharmacists on alcohol-based hand sanitizer production and utilization for COVID-19 prevention in Addis Ababa, Ethiopia: A descriptive phenomenology study
Globally, the safety of patients and healthcare providers is at risk due to health care-associated infections (HCAIs). World Health Organization and the Centers for Disease Control and Prevention recommend using alcohol-based hand rub (ABHR) for hand hygiene in healthcare settings to prevent HCAIs. Irrational use of ABHR will have undesirable consequences including wastage of products, exposure of healthcare providers to infections and emergence of microbial resistance to the alcohol in hand sanitizers. This study aimed to explore the perspective and experiences of compounding pharmacists on production and utilization of ABHR solution for coronavirus disease in 2019 (COVID-19) prevention in public hospitals of Addis Ababa, Ethiopia. A descriptive qualitative study using in-depth interview of 13 key-informants serving as compounding pharmacists in public hospitals of Addis Ababa, Ethiopia, was conducted. The study participants were identified and selected by purposive sampling. All transcribed interviews were subjected to thematic analysis and transcripts were analyzed manually. The compounding pharmacists in this study had a mean age of 30.6 (±3.1) years and nine of the thirteen participants were men. Ten participants believed that the compounding practice in their respective sites followed the principles of good compounding practice. More than half of the participants did not believe that ABHR products were used rationally in health facilities. They argued that users did not have enough awareness when and how to use sanitizers. Most of the interviewees reported that compounding personnel had no formal training on ABHR solution production. Study participants suggested incentive mechanisms and reimbursements for experts involved in the compounding of ABHR solutions. Three of the compounding pharmacists indicated that ABHR production in their setting lack compliance to good compounding practice due to inadequate compounding room, quality control tests, manpower and equipment. Despite this, most study participants preferred the in-house ABHR products than the commercially available ones. Thus, training, regular monitoring and follow-up of the hospital compounding services can further build staff confidence.
- 28 April 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (4) , e0250020
Open AccessPerspectives of compounding pharmacists on alcohol-based hand sanitizer production and utilization for COVID-19 prevention in Addis Ababa, Ethiopia: A descriptive phenomenology study
Globally, the safety of patients and healthcare providers is at risk due to health care-associated infections (HCAIs). World Health Organization and the Centers for Disease Control and Prevention recommend using alcohol-based hand rub (ABHR) for hand hygiene in healthcare settings to prevent HCAIs. Irrational use of ABHR will have undesirable consequences including wastage of products, exposure of healthcare providers to infections and emergence of microbial resistance to the alcohol in hand sanitizers. This study aimed to explore the perspective and experiences of compounding pharmacists on production and utilization of ABHR solution for coronavirus disease in 2019 (COVID-19) prevention in public hospitals of Addis Ababa, Ethiopia. A descriptive qualitative study using in-depth interview of 13 key-informants serving as compounding pharmacists in public hospitals of Addis Ababa, Ethiopia, was conducted. The study participants were identified and selected by purposive sampling. All transcribed interviews were subjected to thematic analysis and transcripts were analyzed manually. The compounding pharmacists in this study had a mean age of 30.6 (±3.1) years and nine of the thirteen participants were men. Ten participants believed that the compounding practice in their respective sites followed the principles of good compounding practice. More than half of the participants did not believe that ABHR products were used rationally in health facilities. They argued that users did not have enough awareness when and how to use sanitizers. Most of the interviewees reported that compounding personnel had no formal training on ABHR solution production. Study participants suggested incentive mechanisms and reimbursements for experts involved in the compounding of ABHR solutions. Three of the compounding pharmacists indicated that ABHR production in their setting lack compliance to good compounding practice due to inadequate compounding room, quality control tests, manpower and equipment. Despite this, most study participants preferred the in-house ABHR products than the commercially available ones. Thus, training, regular monitoring and follow-up of the hospital compounding services can further build staff confidence.
- Open Access
- 1 February 2021
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. ume 13, 37-46
Alcohol-Based Handrub Utilization Practice for COVID-19 Prevention Among Pharmacy Professionals in Ethiopian Public Hospitals: A Cross-Sectional Study
Purpose: Rubbing the hands with alcohol-based handrub (ABHR) is globally recommended as the preferred approach to prevent healthcare-associated infections in most routine encounters with patients, except in cases handwashing with soap and water is advised. Inappropriate utilization of ABHR could have detrimental effects, most importantly during the coronavirus disease (COVID-19) pandemic, which include exposure of healthcare professionals to healthcare-associated infections and the development of resistant microorganisms. In a hospital setting, the utilization of ABHR among frontline healthcare workers including pharmacy professionals is low. Therefore, the purpose of this study was to explore the current practice of hand rubbing among pharmacy professionals in public hospitals of Addis Ababa during the pandemic of COVID-19. Methods: The study was a cross-sectional study using a self-reported questionnaire conducted among pharmacy professionals in public hospitals found in Addis Ababa from 10th May to 9th June, 2020 to recognize ABHR utilization rate. Data were collected on a sample of 384 pharmacy professional by a self-administered questionnaire. Data analysis was done using software for the statistical package for social science version 25.0. To identify the significant predictors of ABHR utilization practice bivariable and multivariable logistic regressions were carried out. Crude odds ratio and adjusted odds ratio with 95% confidence interval were calculated to determine the predictors. Results: Out of 384 participants, three hundred and four participants were included in the final analyses after the exclusion of incomplete responses. Female participants represented 41.4% of the study participants. More than half (58.9%) of the pharmacy professionals had sufficient knowledge on ABHR utilization for COVID-19 prevention. Similarly, 56.6% of pharmacy professionals had positive attitude towards ABHR for COVID-19 prevention. But only 35.9% of the study participants had good ABHR utilization practice. Conclusion: Despite the modest level of knowledge and attitude towards ABHR, pharmacy professionals’ utilization practice of ABHR for COVID-19 prevention was found to be suboptimal. Provision of ABHR solutions through hospitals and increasing the awareness of pharmacy professionals on ABHR needs to be encouraged.
- 1 February 2021
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. ume 13, 37-46
Open AccessAlcohol-Based Handrub Utilization Practice for COVID-19 Prevention Among Pharmacy Professionals in Ethiopian Public Hospitals: A Cross-Sectional Study
Purpose: Rubbing the hands with alcohol-based handrub (ABHR) is globally recommended as the preferred approach to prevent healthcare-associated infections in most routine encounters with patients, except in cases handwashing with soap and water is advised. Inappropriate utilization of ABHR could have detrimental effects, most importantly during the coronavirus disease (COVID-19) pandemic, which include exposure of healthcare professionals to healthcare-associated infections and the development of resistant microorganisms. In a hospital setting, the utilization of ABHR among frontline healthcare workers including pharmacy professionals is low. Therefore, the purpose of this study was to explore the current practice of hand rubbing among pharmacy professionals in public hospitals of Addis Ababa during the pandemic of COVID-19. Methods: The study was a cross-sectional study using a self-reported questionnaire conducted among pharmacy professionals in public hospitals found in Addis Ababa from 10th May to 9th June, 2020 to recognize ABHR utilization rate. Data were collected on a sample of 384 pharmacy professional by a self-administered questionnaire. Data analysis was done using software for the statistical package for social science version 25.0. To identify the significant predictors of ABHR utilization practice bivariable and multivariable logistic regressions were carried out. Crude odds ratio and adjusted odds ratio with 95% confidence interval were calculated to determine the predictors. Results: Out of 384 participants, three hundred and four participants were included in the final analyses after the exclusion of incomplete responses. Female participants represented 41.4% of the study participants. More than half (58.9%) of the pharmacy professionals had sufficient knowledge on ABHR utilization for COVID-19 prevention. Similarly, 56.6% of pharmacy professionals had positive attitude towards ABHR for COVID-19 prevention. But only 35.9% of the study participants had good ABHR utilization practice. Conclusion: Despite the modest level of knowledge and attitude towards ABHR, pharmacy professionals’ utilization practice of ABHR for COVID-19 prevention was found to be suboptimal. Provision of ABHR solutions through hospitals and increasing the awareness of pharmacy professionals on ABHR needs to be encouraged.